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Abstract 
 
CRTAC (Cartilage Acidic Protein) firstly identified as a chondrocyte marker in humans 
and implicated in a number of diseases. This ancient protein is present from prokaryotes 
to vertebrates and the teleost are the only group that contain duplicates 
(CRTAC1/CRTAC2). The structure of CRTACs is poorly characterized and was the 
starting point of the present study.  
To establish the molecular and structural characterization of CRTAC, three recombinant 
proteins [human (h) CRTAC1 and sea bass (Dicentrarchus labrax, dl) CRTAC1 and 
CRTAC2] were over-expressed in E.coli as inclusion bodies and their identity was 
confirmed by mass spectrometry. The resulting refolded recombinant proteins were 
obtained with a productivity of 11,51, 8,4 and 11,9 mg of protein per gram of biomass 
for hCRTAC1, dlCRTAC1 and dlCRTAC2 respectively and approximately 23,48%, 
9,09% and 33,46% of, hCRTAC1, dlCRTAC1 and dlCRTAC2 were lost as insoluble 
aggregates. Size exclusion chromatography revealed the presence of mostly soluble 
aggregated forms of piscine CRTACs and a mixture of aggregates and monomeric form 
for hCRTAC1. Spectroscopic studies of human CRTAC1 and sea bass 
CRTAC1/CRTAC2 showed that all proteins possess secondary and tertiary structure 
and are particularly rich in β- pleated sheet structure (≈40%), have ≈10,3% alpha-helix 
and the remainder is disordered. The thermal stability of CRTAC´s structure was 
assessed considering heating (from 20-90ºC) and freezing (-80ºC). CRTACs retain their 
native secondary and tertiary structures upon heating, however a slight loss of structure 
was observed for hCRTAC1 at 60ºC. Freezing induced loss of secondary structure and 
conformational changes more pronounced for hCRTAC1 and third cycle of dlCRTAC2 
and less perceptible for dlCRTAC1. Amyloid formation by CRTACs was assessed in 
Thioflavin-T assays and a decrease in fluorescence was observed after incubation. In 
summary, CRTAC´s have propensity to form soluble aggregates that are highly 
thermostable and these structural properties are conserved from teleosts to humans. 
 
Keywords: CRTAC; β-sheet; thermostability; diseases; amyloid; structure 
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Resumo 
 
A CRTAC (proteína acídica da cartilagem) é uma proteína da matriz extracelular,  
inicialmente identificada em humanos como marcador de condrócitos e que está 
também associada a várias doenças, como a esclerose múltipla. Esta proteína ancestral 
está presente desde os procariotas até aos vertebrados e os teleósteos são o único grupo 
que contém o gene duplicado (CRTAC1/CRTAC2). Ambas as proteínas apresentam 
estrutura similar e possuem na região N-terminal um domínio semelhante ao das cadeias 
α presente nas integrinas,  mas diferem na região C-terminal pelo facto da CRTAC1 ter 
um domínio adicional descrito como  um factor de crescimento epidérmico com ligação 
a iões Ca2+ . A estrutura conservada das CRTAC indica que estas proteínas podem ter  
uma função importante que ainda não foi identificada e o facto da sua estrutura estar 
pouco caracterizada foi o objecto deste estudo.  
Para o estudo de caracterização molecular e estrutural das CRTAC, três proteínas 
recombinantes [hCRTAC1 humana e CRTAC1 e 2 de robalo (Dicentrarchus labrax 
,dl)] foram sobrexpressas como corpos de inclusão em E.coli e a sua identidade foi 
confirmada por espectroscopia de massa. Após a solubilização, a purificação e o 
“refolding”, a produtividade das proteínas recombinantes resultantes foi de, 11,89 para a 
hCRTAC1, 8,4 para a dlCRTAC1 e 11,9 para a dlCRTAC2, expressa em mg de 
proteína obtida por g de biomassa. Durante este processo, foram registadas perdas 
proteicas na forma de agregados insolúveis de aproximadamente 23,48% de hCRTAC1, 
9,09% de dlCRTAC1 e 33,46% de dlCRTAC2. Análises de cromatografia de exclusão 
molecular, das proteínas CRTAC solubilizadas, revelaram a presença de agregados de 
elevado peso molecular da dlCRTAC1 e 2 de peixes e uma mistura de agregados e 
monómero da CRTAC1 humana. Os estudos espectroscópicos, demonstraram que, as 
proteínas recombinantes CRTAC têm estrutura secundária e terciária e que a sua 
estrutura secundária é particularmente rica em folha-β (≈40%), tendo apenas 10,3% de 
hélice-α e a restante estrutura é desordenada.  
Neste estudo foi avaliada a estabilidade térmica da estrutura das CRTAC, considerando 
o efeito do aquecimento (de 20º a 90ºC) e do congelamento em vários ciclos (-80ºC). Os 
resultados indicaram que, as CRTAC mantêm a sua estrutura secundária e terciária após 
o aquecimento, no entanto, no caso da CRTAC1 humana foi observada uma ligeira 
perda de estrutura a partir dos 60ºC. O efeito do congelamento induziu a uma perda de 
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estrutura secundária e também a alterações conformacionais mais evidentes na 
CRTAC1 humana relativamente á dlCRTAC1 e dlCRTAC2 de peixes.  
A capacidade de formação de fibrilas amilóides pelas CRTAC, sob certas condições de 
incubação, foi avaliada utilizando ensaios com Tioflavina-T. Após a incubação foi 
observada uma diminuição da fluorescência e estes resultados sugerem que, as 
CRTAC´s podem facilmente formar agregados de grandes dimensões com propriedades 
não-amilóides que, podem ser degradados ou sair de solução após longos periodos de 
incubação. Admite-se a hipótese de que tais agregados possam ser estruturas funcionais. 
Resumindo, as proteínas CRTAC tendem a formar agregados solúveis que são 
altamente termoestáveis e estas propriedades estruturais são conservadas desde os 
teleósteos até aos humanos.  
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Abbreviations 
 
CRTAC- Cartilage acidic protein 
 
CD- Circular dichroism 
 
dlCRTAC1/2- Sea bass (Dicentrarchus labrax) Cartilage Acidic Protein ½ 
 
ECM- Extracellular matrix 
 
hCRTAC1 – human Cartilage acidic protein 1  
 
MW-Molecular Weight 
 
MRW- Mean residue weight 
 
SDS-PAGE- Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis 
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CHAPTER I 
General Introduction
 11 
1.1 Framework on Biotechnology 
 
The production of a recombinant protein is a biotechnological process because it results 
in a engineered form to produce a protein. In this process the production of  
heterologous protein by a host organism  generate large quantities of proteins with 
biotechnological potencial interest.  
The biological diversity of the marine environments is a powerful resource for the 
discovery of new bioactive compounds (proteins, drugs, biomaterials etc.) with high 
potential for exploitation by biotechnology. In the present study novel marine derived 
biomolecules (proteins), with potential biotechnological interest will be explored.  
 
1.2 Protein structures and functions 
 
1.2.1 Importance of the study of protein structures 
 
Proteins are the most abundant macromolecules in biological systems and they are 
involved in practically all structural and functional properties of life. 
Between various functions played by proteins, several can be highlight: enzymatic 
catalyses, hormone regulation, support, movement and protection. Proteins are 
constituted by a linear association of amino acids which ultimately determine the 
protein’s organization in different structural levels: the secondary, tertiary and 
quaternary structure. The wide range of functions that proteins have the ability to play is 
a consequence of their elaborate three-dimensional structures, which allow them to 
convert forms of energy or generate the essential structural parts of an organism 1. The 
three dimensional structure of proteins is a source of important information because it 
gives the various responses, such as shape and domain structure, protein classification, 
prediction of function for uncharacterized proteins, interaction with other 
macromolecules, interactions with small ligands, evidence for enzyme mechanism, 
structure-based drug development, post-translational modifications and experimental 
evidence for trans-membrane domains. 
 
 
 
1.2.2 Protein structural organization  
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The structural organization of proteins is divided in 4 main levels: primary, secondary, 
tertiary and quaternary. The primary structure is simpler and results from a polymer of 
amino acid linked by a peptide bond and the protein acquire a linear conformation. The 
secondary structure is associated with the structural arrangements that result from the 
convolution process of the polypeptide chain. The tertiary structure is the three-
dimensional visualization that depended of secondary structure. The Quaternary 
structure refers to the spatial arrangement of subunits and the type of their interactions.  
The secondary structure of proteins is classified in two main structural arrangements: α-
helix and β-sheets. This arrangements sometimes are accomplished by structural 
elements called the turn and loops. 
The α-helix is a coiled structure stabilized by intra-chain hydrogen bonds established 
between the hydrogen of N-H on the bottom coil and oxygen of C=O on top coil of the 
main chain. Two or more helixes can form highly stable coiled coils commonly found 
in sequence motif structures, for example in fibrous proteins, globular proteins, growth 
hormone, myoglobin and others.  
The β-sheets are stabilized by hydrogen bonding between polypeptide strands. A 
polypeptide chain, called a β strand, in a β-sheet is almost fully extended rather than 
being tightly coiled as in the α-helix. The β-sheet has formed by linking two or more β 
strands by hydrogen bonds. Adjacent chains in a β-sheet that run in opposite directions 
are called antiparallel β-sheets and in the same direction are called parallel β-sheets. The 
β-sheet is an important structural element in many proteins, such as, for example, fatty 
acid binding proteins (FABP), important for lipid metabolism. The biological 
membranes has formed by lipids, this are a barrier that define the inside and the outside 
of the cell. Our rich β-sheet structure promotes a permeability, diffusion and channel 
formation.  
Turn and loops participate in the interactions between proteins and other molecules. 
(Voet, D. 2004) 
 
1.2.3 Structures and functions relationship  
 
Proteins are involved in several cellular functions. The elucidation of their structure and 
function not only provides a strong basis for the understanding of these processes, but it 
also allows the identification and/or improvement of therapeutic approaches to fight 
against human, animal or plant diseases. Functional proteins can be divided into 
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different groups: 1) enzymes that catalyse chemical reactions of crucial importance for 
living organisms, 2) proteins that regulate the biosynthesis and metabolism of 
RNA/DNA, 3) cellular membrane proteins, membrane-bound proteins are called 
‘transporters’, 4) proteins involved in the signal transductions of hormones and 
neurotransmitters and finally 5) proteins involved in the regulation of ‘life and death’ of 
bacterial and eukaryotic cells.  
It is generally known that, in proteins, helices and strands are connected to each other 
and combined in many different ways. The most common motifs present in proteins are: 
β-hairpin (two antiparallel β-strands connected by a tight turn of a few amino acids 
between them), greek key (4 β-strands folded over into a sandwich shape), helix-loop-
helix as example the “EF-Hand” motif (α-helix bound by a looping stretch of amino 
acids which structure is stabilized by binding calcium ion) and zinc finger (two β-
strands with an α-helix end folded over to bind a zinc ion, important in DNA binding 
proteins). 
Protein domains consist in a conserved part of the protein sequence that can be 
associated with functions and exist independently of the rest of protein chain. Domains 
are distinct functional and/or structural units in proteins. Usually they are responsible 
for a particular function and interaction, contributing to the overall role of a protein 1..In 
this thesis the proteins under study had 3 characteristic domains: ASPIC/UnbV, N-
terminal integrin α-chain like domain and EGF-Calcium binding domain. The 
ASPIC/UnbV domains are a conserved sequence found associated with 
Tetratricopeptide (TPR) in several paralogous proteins in marine bacteria Pirellula 
(Rhodopirellula baltica) 2. These domains were found associated with FG-GAP repeat 
in several eukaryotic integrin-like proteins and in several other bacterial proteins. The 
N-terminal integrin α-chain like domains are involved in inside-out cellular signalling 
mechanism3. The EGF-Calcium binding domains are crucial for protein-protein 
interactions 4.  
 
1.3 Proteins and conformational changes  
 
Proteins are usually flexible and dynamic and can change its shape in response to 
environmental changes or other factors. The form is then called conformation and the 
transition between two forms is called conformational changes. Conformational changes 
 14 
can be induced by various factors such as variation in temperature, pH, voltage, ionic 
concentration, phosphorylation and binding to a ligand 5. 
In the presence of factors that induce conformational changes, the protein will acquire 
structures other than the native one that can compromise its functionality. In certain 
conditions, proteins may have a tendency to misfold or the inability to sustain their 
folded state and this can lead to the phenomenon of protein aggregation. Protein 
aggregates are classified on the basis of in vivo and in vitro, and ordered and disordered. 
Amyloid fibrils are the example of ordered aggregates, both in vivo and in vitro. 
Inclusion bodies are the example of disordered aggregates in vivo, these are formed in 
the refolding of denaturant-unfolded protein or under mild conditions at native high 
protein concentration 6 
When producing recombinant proteins the major problem encountered is the formation 
of inclusion bodies. These aggregates of insoluble recombinant proteins are normally 
found in bacteria that are forced to produce heterologous protein 7 
 
1.4 Methods to analyse protein structures and protein interactions 
 
The development of structural biology and recombinant DNA technologies made 
possible the production of recombinant proteins. It required the development and 
implementation of more accurate structural studies of the possible conditions in which 
proteins operate, and can then understand their structural changes and their biological 
function 8. 
One of the most used methods to analyze the secondary structure of proteins is circular 
dichroism (CD). Measurement, in solution, of the far-UV CD spectra allows estimate 
the percentage of secondary structure elements of a protein by differential absorption of 
enantiomers in polarized light. The wavelengths used depend on prior knowledge of 
protein structure and the abundance of certain amino acids 9.  
The native tertiary structure of proteins can be determined by x-ray crystallography 
among other methods (e.g. NMR, Cryo electron microscopy).  Fluorescence emission 
spectroscopy can also be used to assess tertiary structure conformational changes or the 
formation of amyloid aggregates (when using the dye thioflavin-T).  
The basis of X-ray crystallography is to determine the atomic coordinates of a 
crystallized protein molecule using x-ray diffraction and therefore characterize the 
three-dimensional structure of that protein . The biggest challenge of crystallography is 
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to crystallize a highly concentrated sample of purified protein as this process is 
dependent on multiple parameters, such as pH, temperature, protein concentration, 
solvent, precipitating ions and other ligands 10.  
Fluorescence spectroscopy can reveal conformational changes in the tertiary structure of 
a protein. Proteins have intrinsic fluorescence due to the presence of aromatic amino 
acids (tryptophan, tyrosine, phenylalanine). Proteins can be excited at 280nm and 
usually have a maximum emission between 300-350 nm. A protein folded in its native 
state has characteristic emission spectra. Structural changes (e.g. unfolding) caused by 
different factors (e.g. temperature, chemicals, pH, ligands, etc) can be detected by a 
shift in the emission spectra, for example due to exposure of the aromatic amino acids 
buried in the native conformation.  
Fluorescence can also be used to identify protein amyloid aggregates as the ones present 
in diseases like Alzheimer’s disease, Parkinson’s disease or type II diabetes. In this case 
a dye, Thioflavin-T is added to the protein sample. When bound to highly β-sheet rich 
structures, as the ones of amyloid aggregates, Thioflavin-T emits enhanced fluorescence 
and a shift of its emission maximum.  11. 
 
1.5 The Cartilage Acidic Protein (CRTAC) 
 
1.5.1 Human CRTAC1 
 
The human cartilage acidic protein 1 (CRTAC1) also known as chondrocyte expressed 
protein 68kDa (CEP-68), was first described as a chondrocyte biomarker 12 with ability 
to distinguish human chondrocytes from osteoblasts and mesenchymal stem cells, in 
culture 13. Recently CRTAC1 has also been described as a potential therapeutic target 
for detection/monitoring damages in cartilage and associated to diseases of the human 
cardiovascular, hematological, neurological, respiratory and urinary systems 14,  
although its function remains unknown.  In studies of patients with multiples sclerosis 
was found the CRTAC-1B transcript in cerebrospinal fluid 15 and expression in several 
brain regions of embryonic mouse, including olfactory bulb, hippocampus, cerebral 
cortex, thalamus and spinal cord 16. CRTAC1 was found associated to glomus tumors in 
neurofibromatosis type 1 disease 17. Recently in studies of human keratoconus was 
found CRTAC1 expressed in the cornea. 18 
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CRTAC1 gene encodes a glycosylated extracellular matrix protein that is found in 
articular cartilage. This acidic protein is composed to 661 amino acids, a N-terminal 27 
amino acids long signal peptide and an EGF-Like Ca2+ binding motif near the C-
terminal. The presence of seven phenylalanine-glycin (FG )-glycin-alanin-prolin (GAP) 
domains and Arginine-glycine-aspartate (RGD) integrin-like binding motifs suggests 
that CRTAC1 may be involved in cell-cell interactions or cell-matrix interactions 14. 
The human CRTAC1 show two transcript variants (CRTAC1-A and CRTAC1-B) that 
result from alternative splicing. The CRTAC1-A transcript were found expressed in 
human brain (low levels), lung, blood, chondrocytes, and transcript CRTAC1-B in brain 
(high levels), eye and pineal gland. The ortologs of CRTAC1 were identified in 
chimpanzee house mouse, Norway rat, domestic cattle, pig, dog chicken, lizard, 
zebrafish, torafugu, green pufferfish and japonese medaka 19. 
 
1.5.2 Piscine CRTAC1/CRTAC2  
 
Analysis of sea bream (sparus auratus) pituitary gland expressed sequence tags (EST)  
reveal a transcript homologue to human CRTAC1 and a CRTAC isoform that lacks the 
C-terminal calcium binding EGF domain. This smaller gene was called CRTAC2. The 
two isoforms of CRTAC (CRTAC1 and 2) have emerged in teleost fish as a result of the 
teleost specific whole genome duplication 20.  
The CRTAC1 and 2 are highly expressed in the liver and kidney followed by nervous 
tissues such as brain, pituitary and spinal cord in teleost fishes19 21. CRTAC’s form 
aggregates under non reducing conditions and different size distributions are found in 
tissues (CRTAC1 and 2 monomer with 69 kDa and 56,9 kDa respectively and a dimer 
of 120kDa)21 
 
1.5.3 CRTAC1/CRTAC2 protein structures  
 
CRTAC1 as CRTAC2 both share the same domains, except the EGF-like calcium 
binding domains, present in CRTAC1 (Fig 1). In silico analysis predict one N-terminal 
integrin α-chain-like region combined with ASPIC/UnbV domain suggesting the 
possibility of alternative functions for this region.  
The ASPIC and UnbV domain is a β-strand-rich region with unknown functions that is 
to our knowledge exclusively found in CRTAC1/CRTAC2 protein family19. The N-
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terminal integrin α chain-like domain is a receptor domain of integrins involved in 
inside-out signalling mechanisms through the cell membrane. 
 
 
 
Fig. 1 Structural domains of CRTAC family members.  SP- Signal peptide, integrin alpha 
chain-like- responsible for cellular signalling mechanism cell-cell/cell-matrix interactions, 
ASPIC/UnbV- Unknown ancestral domain, EGF- Epidermal growth factor domain. 
 
The structure of this receptor domain is composed of a seven-bladed β-propeller and 
each blade is composed of four antiparallel β-sheets 19. Homology model built for sea 
bream CRTAC2 (sbCRTAC2) N-terminal region also predicts a seven-bladed β-
propeller structure for this region (Fig 2A). Mapping of sbCRTAC2 β-propeller 
structure revealed five Calcium binding β hairpin loops located in the lower face of 
CRTAC2 propeller assumed as essential for molecular recognition mechanisms (fig 2). 
These Calcium binding motifs, composed of up to 12 residues, with acid residues in 
position 1,3,5 and 9 that are responsible for the coordination with calcium ion (Fig 2B) 
19. The predicted secondary structures of CRTAC2 showed that 9% of the molecule is 
α-helix, 30% is extended strand and 60% is random coil. 
 
 
 
 
 
 
 
 
 
  
NH2$
NH2$
SP$ Integrin$alpha$chain3like$ ASPIC/UnbV$
SP$ Integrin$alpha$chain3like$ ASPIC/UnbV$ EGF$
COOH$
COOH$
CRTAC2$
CRTAC1$
1 
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Fig 2 Structure of sea bream CRTAC2 modelling (adapted from 19). Upper and lateral views of 
CRTAC2 β –propeller and in different colours the four antiparallel strands of each blade. (A) 
W1 to W7 represent the seven FG-GAP repeats of the N-terminal integrin alfa chain-like 
domain; β1 to β4 represent the β-hairpin loops when hypothetical calcium ions bind (B) 
Hypothetical calcium binding ions (yellow balls) located in the lower face of the propeller.  
 
 
1.5.4 CRTAC1/2 biochemichal/biophysical characterization and related functions 
 
Biochemical and biophysical studies recently performed on sea bream recombinant 
CRTAC2, demonstrated that there is a tendency for aggregate formation in tissues, 
which is majorly insoluble 21. The formation of these aggregates and their subsequent 
characterization may be the key to understanding its function in the degenerative 
diseases implications. Studies conducted have shown the presence of CRTAC1 in 
patients with multiple sclerosis, being the main cause of this disease the amyloid plates 
formation.  
Previous studies in predicted structural modelling showed the existence of five binding 
sites of the calcium ions, but more recent studies have shown that there are six binding 
sites and calcium binding does not induce secondary or tertiary structure modifications, 
suggesting a conformational stability 21.  
Anjos et al. have demonstrated that CRTAC2 probably aggregate before the loss of the 
secondary and tertiary structure until temperatures of 90 °C. This ability for aggregation 
and your thermostability may suggest important function still unknown. 
 
 
 
 
 
5B. Redruello et al. / Gene 456 (2010) 1–14
5B. Redruello et al. / Gene 456 (2010) 1–14
A B 
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1.6 Objectives 
 
The general aim of the present thesis is to characterize the structure, stability and 
aggregation properties of human CRTAC1 and piscine CRTAC1 and CRTAC2 by 
comparative analysis. This involves the construction of a pipeline to produce 
recombinant CRTAC proteins and a number of biophysical studies. Three main tasks 
are proposed: 
 
1) Large scale production and purification of the 3 recombinant CRTAC proteins 
(hCRTAC1, dlCRTAC1 and dlCRTAC2). This task involves the application of 
several techniques such as protein expression, solubilisation, purification, 
refolding and dialysis. The recombinant proteins production will be monitored 
and the proteins analysed by SDS-PAGE. The identity of the CRTACs will be 
confirmed by MALDI-TOF and western blot.   
 
2) Structural characterisation of native CRTACs and evaluation of their thermal  
stability using circular dichroism and intrinsic fluorescence emission 
spectroscopy. In this study it will be explored the effect of heating and freezing 
on the secondary and tertiary structure of the proteins. 
 
3) Analysis of CRTAC’s ability to aggregate and form amyloid structures.  In this 
task the proteins will be incubated and the formation of aggregates will be 
assessed. The putative formation of amyloid-like aggregates will be tested using 
the dye Thioflavin-T. 
 
 
The scientific contribution of the thesis was to increase the knowledge about the 
structure of the duplicates CRTAC1 and 2 that could be of relevance to the 
biotechnological and pharmaceutical industries. 
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1. Introduction 
 
Cartilage acidic protein (CRTAC) is an extracellular matrix (ECM) protein of unknown 
function firstly identified in humans as a chondrocytes marker with ability to distinguish 
human chondrocytes from osteoblasts and mesenchymal cells in culture12. It is an 
evolutionary ancient protein that is found from prokaryotes to vertebrates and its 
conservation suggests an important, although as yet unknown, function. Two isoforms 
of CRTAC (CRTAC1 and 2) were found in teleost fish as a result of the teleost specific 
whole genome duplication 20 and are homologues of the recently identified CRTAC1 in 
humans (hCRTAC1). Both proteins have a similar structure and possess a conserved N-
terminal seven-bladed β-propeller structure containing an integrin α chain-like Ca2+ -
binding motif. However, CRTAC1 has acquired a C-terminal (EGF)-Calcium binding 
domain 19, crucial for protein–protein interactions 22 which is absent in CRTAC2. In 
silico analysis predict also the presence of an ASPIC/UnbV domain combined with a N-
terminal integrin α chain-like domain which is involved in inside-out cellular signaling 
mechanisms through the cell membrane 23.The ASPIC/Unbv domain is a β- strand-rich 
region, exclusively found in bacterial proteins and in eukaryotic integrin-like proteins 
(ex: CRTAC’s family) 24. Structural prediction analysis identified seven FG-GAP 
amino acid repeats present in the N-terminal region of the CRTAC1/CRTAC2 family 
members. This region forms a conserved seven-bladed β-propeller structure containing 
Ca-binding β-hairpin loops and each blade of the propeller is composed of four 
antiparallel β-sheets 19.  
In addition to the chondrogenic tissue, hCRTAC1 was also found in lung, brain, eye, 
pineal and parathyroid gland 14. A CRTAC1B splice variant is the dominant transcript 
in brain 12 and is an antagonist of Nogo receptor-1 playing a key role in olfactory tract 
formation 16. The distribution of CRTAC2 in teleosts is similar to human CRTAC1 and 
their broad tissue distribution suggests that it may not only function as an ECM protein 
19. Interest in this protein has been linked to its localization in articular cartilage and 
related diseases and it has also been associated with multiple sclerosis, bone fracture, 
neurofibromatosis type 1-associated glomus tumors 17. However CRTAC’s relation to 
pathogenesis is unclear. Recent studies showed the increase of CRTAC1 expression in 
patients with multiple sclerosis 15 and this disease is strongly related to  formation of 
amyloid plates.  
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Previous biochemical and biophysical studies revealed that sea bream CRTAC2 is a highly	  thermostable	  β-­‐sheet	  ordered	  protein	  that	  binds	  Calcium	  with	  high	  affinity	  and	  tends	  to	  form	  soluble	  aggregates	  in	  vivo	  21.	  Aggregate	  formation	  by	  sbCRTAC2	  native	   protein	   was	   also	   observed	   in	   tissues	   like	   pituitary	   and	   liver	   21.	   In	   fact	  
proteins with a β-propeller fold like CRTAC frequently play key biological roles and 
have been directly or indirectly associated with human diseases 25 such as human retinal 
degeneration, Kallmann syndrome or amyloid diseases, such as Alzheimers or 
atherosclerosis 26. The formation of aggregates by CRTAC and their subsequent 
characterization may be the key to understanding its putative role in degenerative 
diseases.  
Three recombinant CRTAC proteins were produced, hCRTAC1 and piscine CRTAC1 
andCRTAC2, and comparative biophysical analysis were performed aiming to 
characterize CRTAC structure and assess its stability and propensity for fibrils 
formation. 
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2. Material and Methods 
 
2.2. Recombinant CRTACs expression 
2.2.1	  Large	  scale	  production	  of	  human	  CRTAC1	  and	  piscine	  CRTAC1/CRTAC2	  
recombinant	  proteins	  
 
Glycerol stocks of E. Coli transformed with the recombinant expression constructs 
pET11a/CRTACs had been previously prepared and were used as starting material in this 
project. Briefly, the piscine forms of CRTAC1 and 2 (dlCRTAC1 and 2) were isolated 
from cDNA of sea bass (Dicentrarchus labrax, dl) larvae, cloned into pGEMT-easy 
vector (Novagen) and subcloned into pET11a expression vector (Novagen). Human 
CRTAC1 (hCRTAC1) is described in the literature and was purchased as an 
ORFEXPRESS™ Gateway PLUS shuttle clone from GeneCopoeia and subcloned into 
pET11a expression vector.  Vector inserts were analysed by PCR followed by restriction 
digestion and sequencing to confirm the authenticity and the correct reading frame of the 
inserts. Competent E. Coli (BL21 (DE3) and OrigamiTM2 DE3, Novagen) were 
transfected with the constructs (pET11a/hCRTAC1; pET11a/dlCRTAC1; 
pET11a/dlCRTAC2) and tested for high expression level of the mature CRTACs forms.  
Single clones of BL21 (DE3)- hCRTAC1 and OrigamiTM2(DE3)- dlCRTAC1 and 
dlCRTAC2 were independently inoculated in LB media containing Ampicillin (100 
µg/ml) and grown overnight at 37 ºC and 250 rpm. This culture was further used to 
inoculate large scale cultures (2 or 1,5 L of LB enriched with 35 mM K2HPO4, 4 mM 
KH2PO4, 4 mM glucose and Ampicillin (100 µg/ml)) that were grown at 37 ºC and 250 
rpm until they attained an OD600nm=0.6-0.8. Expression was induced by adding 0.8 
mM IPTG and was allowed to proceed for 6 h at 30 ºC, in all CRTAC’S and additional 
optimization for 12h at 30ºC was carried out for hCRTAC1.  Bacterial pellets were 
harvested by centrifugation for 10 min at 7500 rpm, 4°C, and lysed in lysis buffer [200 
mM Tris–HCl pH 8, 500 mM NaCl, 0.1 mg/ml lysozyme (Sigma, UK), 0.025 mg/ml 
DNase I (Sigma, USA), 4.2 mM MgCl2, 1 mM phenylmethanesulfonyl fluoride (Sigma, 
US)] at a ratio of 6 ml of buffer per gram of E. coli. The mixture was incubated for1 h at 
room temperature with agitation followed by 3 freeze/thaw cycles and sonication (2 
cycles at 30 sec and 1 cycle at 1 min) to ensure complete lysis. After centrifugation for 
10 min. at 15000 rpm, 4 ºC, the insoluble protein fraction was solubilized in denaturing 
buffer (8 M Urea, 50 mM Tris pH 8, 100 mM NaCl, 10 mM EDTA) at a ratio of 3 ml of 
buffer per gram of pellet for 16 h at 4 ºC with gentle stirring. Soluble and insoluble 
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protein fractions were analyzed by SDS-PAGE using a 10% polyacrylamide gel to 
confirm expression.  
 
2.2.2 CRTAC’s purification and refolding  
 
Purification and analytical separation of the recombinant dlCRTAC1/ dlCRTAC2 and 
hCRTAC1 was carried out by preparative SDS-PAGE with continuous elution 
electrophoresis using a Model 491 Prep Cell (Bio-Rad, Portugal). In this method, the 
sample moves through a cylindrical gel where proteins separate into ring-shaped bands. 
Individual proteins bands migrate according to size to the bottom of the gel into a 
collection chamber from where they are pumped into an external fraction collector. The 
resolving gel (75x37mm) was composed of 10% polyacrylamide in 0.375 M Tris-HCl, 
pH 8.8 and the polymerization occurred into a cylindrical cast for 4 hours. The stacking 
gel (25x37mm) was of 4 % polyacrylamide in 0,125 M Tris-HCl, pH 6.8 and was 
polymerized for 2 hours. The resolving gel after polymerization had approximately 
between 7.5-8.4 cm and stacking gel had 1.2-3.5 cm. Protein sample was mixed (6 or 
8ml) with 2x sample buffer (0.0625 M Tris–HCl pH 6.8; 0.025% bromophenol blue; 
10% glycerol, 200 mM DTT) respectively and heated at 100 ºC for 5 min. 
Electrophoresis was carried out using 0,025 M Tris-HCl; 0,19 M glycine; 0,1% SDS pH 
8.3 as running buffer and run at a constant power of 12W/80 mA approximately 8-10h, 
maintaining a constant temperature (18ºC) until the ion front (bromophenol blue) has 
migrated out the gel. Protein fractionated was collected into the elution chamber and 
collected in 2,5ml/fraction at 8ºC in 1x Elution buffer (0,192 M Glycine; 25 mM Tris-
base). The eluted recombinant proteins were detected by analytical SDS-PAGE gel 10% 
and coomassie blue or silver staining (Biorad Silver Kit, Portugal). Pure fractions were 
pooled and concentrated >10x using Ultrafree-15 centrifugal filter devices with a 
molecular cut-off of 5 kDa (Millipore, Bedford, UK). The refolding process of the three 
CRTAC proteins was achieved by successive dialysis against different buffers (1st - 0.5 
M Urea, 100 mM Glycine, 100 mM Tris-HClpH 8, 0.4 M L-arginine, 0.5 mM 
Glutathione oxidized, 5 mM Glutathione reduced; 2nd - 100 mM Glycine, 100 mM Tris-
HCl pH 8, 0.2 M L-arginine, 0.5 mM Glutathione oxidized, 5 mM Glutathione reduced; 
3rd - 100 mM Tris-HCl pH 8, 100 mM Glycine, 0.1 M L-arginine, 0.25 mM Glutathione 
oxidized, 2.5 mM Glutathione reduced; 4th - 100 mM Tris-HCl pH 8,100 mM Glycine , 
5th - 100 mM Tris-HCl pH 8, 250 mM NaCl). Each dialysis was performed at 4 ºC 
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during 16 h with gentle stirring and to eliminate protein precipitates the samples were 
centrifuged for 10 min at 12000 rpm, 4ºC in the end of the dialysis process. The final 
concentration of each protein was determined using the method described by Gill and 
Hippel 27 based on UV absorption at 280 nm and on the molar extinction coefficient 
estimated according to the following equation εM,Gdn.HCl= a εM,,Tyr + b εM,,Trp + c εM,,Cys.  
The process of expression, purification and refolding of the three CRTACs was repeated 
several times whenever necessary to carry out the biophysical experiments experiments 
and the yield of the protein production process was monitored in each step of the 
process (from purification until the final product).  
 
2.3 Molecular Characterization of CRTAC’s 
2.3.1	  MALDI-­‐TOF	  analysis	  
 
Purified recombinant CRTAC´s were resolved on SDS-PAGE (10% polyacrylamide 
gel) and the bands were excised and placed in MilliQ water for protein identification 
analysis conducted by Centro de Genómica y Proteómica (Unidad de Proteómica, 
Faculdad de Farmacia, UCM, Spain). An additional protein band observed during 
dlCRTAC2 expression but with a small molecular weight than the expected for 
CRTAC2 was also identified. The CRTAC’s proteins were subjected in-gel to trypsin 
digestion and the molecular weights of the peptides and amino acid sequences were 
analyzed by MALDI-TOF (Matrix Assisted Laser Desorption Ionization (MALDI) 
tandem Time-of-Flight (TOF) mass spectrophotometer). The peptides fragmentation 
were identified by MS/MS and peptide mass fingerprinting. The results were used for 
database searches using MASCOT software (http://www.matrixscience.com). 
 
2.3.2 Western blot analysis 
 
Western blotting, also known as immunoblotting or protein blotting is used to detect the 
presence of a specific protein in a complex mixture. The western blotting procedure 
relies upon three key steps: the separation of the mixture by size using gel 
electrophoresis, the efficient transference of separated proteins to a solid support and the 
specific detection of the target protein by appropriately matched antibodies.  
The identity and authenticity of CRTAC´s proteins was confirmed by western blot using 
the following specific polyclonal antibodies: commercial goat anti-hCRTAC1 
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(SantaCruz Biotechnology, USA); rabbit anti-dlCRTAC2 serum (produced against a 
specific dlCRTAC2 peptide); rabbit anti-sbCRTAC2 serum (produced against the 
sbCRTAC2 recombinant protein), being the last two available in house. All the 
antibodies in use were previously validated and the titres optimized before the 
beginning of this study.  
The purified CRTAC proteins (1µg per well in duplicates) were separated by SDS-
PAGE (10% polyacrylamide gel) and transferred onto a nitrocellulose membrane 0.2 
µm (Biorad, Portugal) for 2:15 h at 300 mA in a vertical tank transfer system (TE 22 
Mighthy Small Tank Tranfer, Hoeffer, Amersham GE HealthCare. USA). 
Nitrocellulose membrane was stained with Ponceau S dye (Sigma Aldrich, USA) for 
reversible detection of protein bands on membrane. After protein bands detection the 
membrane was blocked with 3% BSA, overnight at 4 ºC for dlCRTAC1 and dlCRTAC2 
and 1h for hCRTAC1 at room temperature. CRTAC proteins immobilized on 
membranes were firstly incubated with primary antibodies (goat anti-hCRTAC1 1/2,500 
for hCRTAC1 and rabbit, anti-sbCRTAC2 (1/300,000) or anti-dlCRTAC2 (1/100,000) 
for dlCRTAC1 and dlCRTAC2 respectively) during 1 h at room temperature or 
overnight at 4 ºC in the case of hCRTAC1. As reaction controls, membrane duplicates 
were incubated with rabbit pre-immune sera using the same dilutions, except for 
hCRTAC1 in which the control was established using pre-absorbed (with 10,4 µM of 
purified hCRTAC1) goat-anti hCRTAC1 1/2,500. Detection was carried out by 
incubating the membranes during 1 h at room temperature with the secondary 
antibodies (1/35,000, biotinylated anti-rabbit IgG, Amersham GE Healthcare, UK or 
1/80,000 HRP-anti-goat IgG, (Amersham GE Healthcare, UK) followed by 
streptavidin–horseradish peroxidase conjugate (1/50,000, Amersham GE Healthcare, 
UK) for the biotinylated secondary antibody. Antibody working dilutions were prepared 
in 1XTBS (50 mM Tris, 150 mM NaCl, pH 7.6). Between each incubation step 
membranes were washed for 3 times during 10 min in 1xTBST.	   Membranes were 
developed by chemiluminescence using ECL™ Prime Western Blotting Detection kit 
(Amersham GE Healthcare, UK) following the manufacturer´s instructions. Images 
were captured by automatic exposure using the ImageQuant LAS 500 (GE healthcare, 
UK) system.  
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2.3.4	  Size	  exclusion	  Chromatography	  
 
Size exclusion chromatography was used to evaluate the formation of aggregates by the 
recombinant CRTAC proteins after purification, concentration and refolding. Separation 
was carried in a Superdex 200 increase 10/300 GL column (GE healthcare, UK) 
connected to an Äkta Purifier (GE healthcare, UK) following the manufacturer’s 
instruction and guidelines. The column was pre-equilibrated with 5 column volumes 
(cv) of water followed by 5 cycles of chromatography buffer (100 mM Tris-HCl pH8, 
250 mM NaCl buffer). Pure CRTACs were dialyzed against the chromatography buffer 
and concentrated to 33 µM, 61 µM and 77 µM for hCRTAC1, dlCRTAC1 and 
dlCRTAC2, respectively. A sample of 1-2 ml size was injected into the column using a 
2 ml loop. The elution of protein peaks was monitored by UV280 nm using the 
UNICORN software (GE healthcare, UK) and the protein factions recovered using a 
fraction collector.  
 
2.4 Structural Characterization of CRTAC’S 
2.4.1	  Circular	  Dichroism	  (CD)	  spectroscopy	  	  
	  
CD was used to analyze and compare the secondary structure and stability of the human 
as piscine CRTACs. Pure CRTACs were dialyzed against water and used at a final 
concentration of 5 µM. Measurements were performed in a Jasco J-810 CD 
Spectropolarimeter using a 1 mm path lenght quartz cell (Hellma). Far-UV spectra was 
recorded between 180-250 nm. Thermal scans were performed to evaluate and compare 
CRTAC’s thermal stability in water between 20 ºC and 90 ºC at 210 nm using a peltier 
unit. The temperature measurements were obtained at rate 1ºC/min.  The effect of low 
temperature (freezing) was also analyzed by measuring a scan between 180-250 nm 
before and after freezing each CRTAC at -80ºC. and measurements normalized to 
maximum emission wavelength. A buffer/water baseline was measured accordingly and 
subtracted from all spectra. A minimum of 3 accumulations were obtained and averaged 
for each measurement. 
Results were expressed in mean residue weight ellipticity ([θ]mrw) in deg.cm2/dmol 
using the equation:[θ]mrw,λ=MRW(θλ)/10lc in which MRW is the mean residue 
weight (molecular weight/N−1 where N is the number of amino acids), θ is the observed 
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ellipticity (in degrees), l is the path length (in cm) and c the protein concentration (in 
g/ml). 
2.4.2	  Fluorescence	  Emission	  Spectroscopy	  
	  
Fluorescence spectroscopy was used to analyse the tertiary structure and thermal 
stability of the CRTACs. Measurements were performed in a Fluoromax3 Horiba 
Scientific using a rectangular quartz cell with a 10 mm path length and excitation at 280 
nm. Emission spectrum was recorded between 290 and 420 nm using a 1 nm slit width.  
Protein samples were prepared in water to a final concentration of 1µM. Thermal 
stability was assessed qualitatively by taking scans at 20ºC and after heating the 
samples to 90ºC. Similarly scans were also taken before and after freezing the samples 
at -80ºC. Scans were analyzed with the program Origin and normalized to the maximum 
emission wavelength for comparison.  
 
2.4.3	  Fibrill	  formation	  analysis	  	  
 
Thioflavin T (ThT) assay was used to evaluate amyloid fiber formation by CRTACs 11. 
Human and piscine CRTAC protein samples were incubated at 37ºC in Tris buffer 100 
mM, 500 mM NaCl, 1mM CaCl2 at pH8 for 20 days to allow potential fibril formation. 
Samples was taken and mixed with ThT to a final concentration of 33 uM, 131 uM and 
153 uM hCRTAC1, dlCRTAC1 and dlCRTAC2 protein, respectively and 20 µM ThT. 
Fluorescence was measured in using a 96 multiwell plate in a Fluorescence plate reader 
(BIO synergy plate reader, BioTek). Excitation and emission were at 450 and 490 nm 
respectively. ThT fluorescence was measured at incubation time T=0 for control.  
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3. Results 
 
3.1 CRTAC’s recombinant proteins expression 
 
The expressed CRTAC’s recombinant proteins were predominantly insoluble. The 
SDS-PAGE analysis of the large-scale production of recombinant CRTAC´s proteins 
revealed that all CRTAC´s were overexpressed in the insoluble cellular fraction as 
inclusion bodies (Fig 1A, B). Inducer concentration and the post-induction growth 
temperature or induction time were optimized in small-scale production however the 
insolubility of the CRTAC´s could not be reverted (results previously obtained by Anjos 
L. and not shown). Theoretical values for the isoelectric point (pI) and molecular weight 
(MW) of the mature CRTAC´s forms preceded by a Met (methionine) were estimated 
by ProtParam Expasy software (http://web.expasy.org/protparam/) and were of pI= 4,97 
and MW= 68,56 kDa for hCRTAC1 and of pI=5,2 and 4,9 and MW= 68,02 and 56,87 
kDa for dlCRTAC1 and 2 respectively. All CRTAC´s proteins were successfully 
produced with the expected molecular weight as predicted and strong bands were 
observed for hCRTAC1 (Fig 1A), dlCRTAC1 and dlCRTAC2 (Fig 1B) in the insoluble 
bacterial extract fraction after expression induction with 0.8 Mm IPTG. hCRTAC1 was 
expressed in E.coli BL21(DE3) strain (no results were obtained for E.coli 
Origami2(DE3)) and two induction times (6 and 12 h) with 0,8 mM IPTG were tested in 
the large-scale production. The results demonstrate an increase in hCRTAC1 protein 
expression with the induction time duplication (Fig 1A). dlCRTAC1 and 2 were 
expressed in both strains (E.coli BL21(DE3) and E.coli Origami2(DE3)), however the 
expression was higher in E.coli Origami2(DE3) and the best induction time was of 6 h 
after small scale optimization (results previously obtained by Anjos L. and not shown ).  
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Fig. 1. Scale-up production analysis of the recombinant CRTAC´s by Coomassie blue stained SDS-PAGE 
(10%).  A) Bacterial lysates from E.coli BL21(DE3) transformed with pET11a/hCRTAC1 construct, note 
the hCRTAC1 expression at different induction times (6 and 12 h) with 0,8 mM IPTG present in the 
insoluble bacterial fraction (red arrow).  B) Bacterial lysates from E.coli Origami2(DE3) transformed 
with pET11a/dlCRTAC1 and pET11a/dlCRTAC2 constructs, note the dlCRTAC1 and dlCRTAC2 
expressed after 6 h of induction with 0,8mM IPTG and presents in the insoluble bacterial fraction (black 
arrows). C) Purified CRTAC´s proteins. Orange square- small molecular weight band identified as 
dlCRTAC2 by MALDI-TOF and described in point 3.2.1; M - molecular weight markers (kDa). 
 
The production line of the recombinant CRTAC´s proteins was preliminary monitored 
(Table 1) by protein quantification in each step of the process (purification/ 
concentration/ refolding) through the UV–vis	   absorption	   at	   280	   nm and molar 
extinction coefficient (Ɛ) 27, that was estimated to be of 52600 M-1 cm-1 for hCRTAC1, 
58050 M-1 cm-1 for dlCRTAC1 and 38270 M-1 cm-1 dlCRTAC2.  
The yield of the process from protein purification until refolding was estimated and 
piscine CRTAC1 and human CRTAC1 (12 h of induction) were obtained with higher 
yield (90.91 % and 76.52 %) and the protein loss was observed only during protein 
concentration step. Significant loss was observed for dlCRTAC2 (≈ 36.46%) mainly 
during protein concentration step after purification and this loss even with less impact 
extends up to the refolding process unlike which was observed for CRTAC1 forms. In 
this case and for all CRTAC1 forms some protein was recovered during the refolding 
process. Protein aggregates and precipitates were visually observed during 
concentration/refolding process and its appearance resembles floating wires. 
100#
75#
50#
MkDa# hC
RTA
C1#
dlC
RTA
C1#
dlC
RTA
C2#
C
Ins
olu
ble
)
Induc,on),me)=12h)
Sol
ubl
e)
Sol
ubl
e)
Ins
olu
ble
)
hCRTAC1#
Induc,on),me)=)6h)
kDa# M
75#
50#
100#
A
100#
Ins
olu
ble
)
Ins
olu
ble
)
Sol
ubl
e)
Sol
ubl
e)
dlCRTAC1# dlCRTAC2#
MkDa#
50#
75#
B
 32 
 
Table1. Preliminary monitoring of the recombinant CRTACs proteins production process. Each step of 
the process from purification, concentration until refolding was monitored by estimation of the total 
protein concentration (mg/ml) and the yield, loss and productivity of process are also presented. 
 
 
✜ Total yield = (Total protein concentration after refolding/ Total protein concentration after Prep Cell 
purification) x 100%.  
!Total loss was estimated by calculating the difference between 100% and total yield (%). 
Productivity was estimated according to the following equation ((volume of Inclusion Bodies 
solubilization buffer* mass of refolded protein)/sample volume. load in Prep Cell)/Total biomass)  
All values in the table are considered preliminary since they refer to a single production process for each 
protein and not include replicates of the process. 
 
The final productivity of purified, refolded solubilized recombinant hCRTAC1 (12h), 
dlCRTAC1 and dlCRTAC2 was respectively, 11,55, 8,4 and 11,9 mg of protein per 
gram of bacteria. Highest productivity was observed for hCRTAC1 (12h) and 
dlCRTAC2, even though the latter have gone significant losses. Remarkable was the 
hCRTAC1 productivity difference (from 3,92 to 11,55 mg of protein/g of biomass)  
obtained with the induction time duplication (from 6 to 12 h) and this results are in 
agreement with which was observed in gel in Fig 1A. The results obtained suggest that 
different E. Coli strains could influence CRTAC´s expression and more induction time 
(12h) will be needed for hCRTAC1 expression in E.coli BL21(DE3), comparatively to 
dlCRTAC1 and dlCRTAC2 expression (6h) in E.coli Origami2(DE3) strain. 
All the recombinant CRTAC´s were obtained with a good purity as observed under 
denaturing conditions in Fig 1C. 
 
Process'steps/Parameters! hCRTAC1'(6h)' hCRTAC1'(12h)' dlCRTAC1'(6h)' dlCRTAC2'(6h)'
Culture'volume'(L)' 1,5' 2'' 2' 2'
Biomass'(g)' 5,23' 13,37'' 9' 10'
Inclusion'bodys'solubilizaBon'buﬀer'(ml)'*' 12,55' 40,11' 21,6' 24'
Sample'volume'load'in'PREPCELL'for'puriﬁcaBon''
(ml)'
6' 8' 6' 3'
Protein'aOer'Prep'Cell'puriﬁcaBon'[mg/ml]''
(Total'volume/Total'concentraBon)'
0,084'
(125ml/10,5mg)'
0,23'
(175ml/40,25mg)'
0,063'
(368ml/23,1mg)'
0,110'
(212ml/23,45mg)'
Protein'aOer'UltrafreeU15'ﬁlter'concentraBon'[mg/
ml]''
(Total'volume/Total'concentraBon)'
1,68'
(7ml/8,3mg)'
2,41'
(9,7ml/23,37mg)'
1'
(20ml/20mg)'
0,84'
(20ml/16,8mg)'
Protein'aOer'Refolding'[mg/ml]'
'(Total'volume/Total'concentraBon)'
1,08'
(9ml/9,8mg)'
2,46'
(12,5ml/30,8mg)'
0,7'
(30ml/21mg)'
0,88'
(17ml/14,9mg)'
Total'yield''(%)'U'from'puriﬁcaBon'unBl'refolding'✜' 93,33%' 76,52%' 90,91%' 63,54%'
Total'loss'(%)'U'from'puriﬁcaBon'unBl'refolding'!' 6,67%' 23,48%'' 9,09%' 36,46%'
ProducBvity'(mg'of'puriﬁed'protein/g'of''biomass)' 3,92' 11,55' 8,4' 11,9'
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3.2 Molecular characterization 
3.2.1	  Identification	  of	  recombinant	  CRTAC´s	  
 
The identity of the purified recombinant CRTAC´s was confirmed by MALDI-TOF 
analysis with a significant score and p<0.05. The MS fingerprint spectra of hCRTAC1, 
dlCRTAC1 and 2 were composed of 21, 20 and 24 tryptic peptides.  MASCOT blast 
search revealed the amino acid sequence for hCRTAC1, dlCRTAC1 and 2. hCRTAC1 
and dlCRTAC1 had the best match with the sequence predicted for   Cartilage Acidic 
protein 1 isoform X1 (Homo sapiens, gi:530393911) and Cartilage Acidic Protein 1 
(Tetraodon nigroviridis, gi: 85838736) respectively. The sequence coverage, the 
nominal mass (Mr) and pI was of 39%, 68,6 kDa and 5.05 for hCRTAC1 and of 29%, 
69,6 kDa and 5.42 for dlCRTAC1. dlCRTAC2 was not possible identify by MASCOT 
blast search in public databases and their identity was confirmed via MASCOT search 
after tryptic digestion but against its own amino acid sequence (translated from the 
amplified full lenght cDNA of Dicentrarchus labrax) provided by us. Both dlCRTAC2 
protein bands, the largest and the smallest indicated in Fig 1B were analyzed by 
MALDI-TOF and the sequence coverage was of 60% for the largest form and 30% for 
the smallest form, the nominal mass (Mr) and pI was of 59.2 and 5.03. MALDI-TOF 
analysis results are shown in appendix 1. 
 
3.2.2 CRTAC’s immunoreactivity  
	  
The immunoreactivity of the purified/refolded recombinant CRTAC’s were confirmed 
by Western blot analysis using specific CRTAC´s polyclonal antibodies (Fig 2). Single 
immunoractive bands were observed for hCRTAC1, dlCRTAC1 and dlCRTAC2 (Fig 3) 
with the expected molecular weights of 68,6 kDa for hCRTAC1, 69,6 kDa for 
dlCRTAC1 and 56,7 kDa for dlCRTAC2, under denaturing conditions and no protein 
degradation was observed. No reaction in Western blot was obtained when anti-
CRTAC´s antibody or antiserum was substituted by pre-absorbed or pre-immune serum 
(Fig 3). Results of antibodies validation assays previously carried out demonstrate that 
human anti-CRTAC1 (not published) and sea bream anti-sbCRTAC221 cross react with 
piscine CRTAC 1 and 2. The antiserum generated against sea bass CRTAC2 specific 
peptide show to be specific for CRTAC2 only (not published). The identity of the 
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CRTAC´s was confirmed and despite the cross-reacting antibodies, discrimination 
between proteins was also possible due to the MW differences between them.  
 
Fig. 3. CRTAC´s immunoreactivity analysis by western blot using polyconal antibodies (anti-
hCRTAC1/anti-sbCRTAC2/anti-dlCRTAC2). Pure CRTAC’s proteins (1 µg) was fractionated by SDS-
PAGE (10%), blotted onto nitrocellulose membrane and imunostained with: (A)-goat anti-hCRTAC1 or 
anti-hCRTAC1 pre-absorbed (1/2,500); (B)-rabbit anti-sbCRTAC2 serum or pre-immune serum 
(1/300,000); (C) rabbit anti-dlCRTAC2 serum or pre-immune serum (1/100,000). The secondary 
antibodys were anti-goat HRP (1/80,000) or biotinylated anti-rabbit (1/35,000) and streptavidin–HRP 
(1/50,000). M — molecular weight markers (kDa). 
 
3.2.3	  CRTAC	  monomers	  and	  aggregates	  
 
Analysis and separation of different molecular weight species formed by the human and 
piscine CRTAC´s were carried out by size exclusion chromatography. hCRTAC1, 
dlCRTAC1 and dlCRTAC2 samples at 33uM, 61uM and 77uM respectively were 
separated in a semi-preparative gel filtration column to obtain final homogenous 
samples in a high concentration suitable for protein crystallography trials 
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Fig. 3. Size exclusion chromatographs of dlCRTAC1 (A), dlCRTAC2 (B) and hCRTAC1 (C) and 
standard chromatograph with proteins of known molecular weight used for qualitative molecular weight 
estimation. Peaks correspond to retention volumes of each protein species: dlCRTAC1 (7.9 and 14.7 ml), 
dlCRTAC2 (7.6 and 15.2 ml) and hCRTAC1 (7.75 and 14.6 ml) or standard proteins (D) as indicated (1- 
Thyroglobulin, 2- gama-globulin, 3- Ovalbulmin, 4- Myoglobin, 5- Vitamin B12) 
 
A chromatograph with proteins of known molecular weight was obtained in order to 
estimate the molecular weight of the CRTAC peaks by comparison. Large peaks with 
lower retention volumes (approximately 7.5 ml) times obtained for dlCRTAC1, 
dlCRTAC2 and hCRTAC1 (Fig 3) correspond to large molecular weights above 670 
kDa as suggested by the standard graph (Fig 3D). Smaller peaks with higher retention 
volumes (approximately 15ml) were obtained for each protein and likely correspond to 
the monomeric form of each CRTAC. Peaks were separately collected and further 
concentrated to use in crystallization trials (future studies). Peaks corresponding to 
dlCRTAC1 and dlCRTAC2 monomer were very small suggesting that the protein is 
mostly aggregated and less stable or less soluble than hCRTAC1.    
 
 
3.3 Structural characterization 
3.3.1	  Freezing	  and	  heating	  does	  not	  induce	  conformational	  changes	  
 
Pure CRTAC proteins dialysed against water were analyzed by Far-UV CD spectra and 
found to to possess secondary structure. Percentage of secondary structure elements was 
estimated using a algorithm CONTIN. The hCRTAC1 showed a negative peak (-
1,0853x103 deg cm2/dmol) at 211,2 nm and 10,3% α-helix, 38% β-sheet and 51,6% 
disordered. dlCRTAC1 showed a negative peak (-9,5017x103)at 211nm and 10,3% α-
helix, 38% β-sheet and 51,6% disordered. dlCRTAC2 showed a negative peak (-
1,00619x103) at 207,6 nm and 10,4% α-helix, 38,1% β-sheet and 51,5% was disordered.  
All CRTACs showed a high β-sheet content and CD spectra suggest high similarity (Fig 
4).  
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Fig 4. Far-UV spectra of purified recombinant CRTAC’S (5uM) in water at room temperature (25ºC), 
scanned from 250 to 180nm.  
 
The thermostability of CRTACs was analyzed by following changes in the spectra 
minimum ellepticity (210 nm) with increasing temperature from   20ºC to 90ºC (Fig. 5). 
No sign of thermal unfolding (thermal state transition) was observed for all the 
CRTACs suggesting a high thermostability There was a slight loss of secondary 
structure after 60ºC which was much more pronounced for hCRTAC1 (to 39.6% from 
at 48,4% at 20ºC) suggesting that human CRTAC might be less thermostable than the 
piscine CRTAC form. CRTAC thermostability had been already described for the sea 
bream CRTAC221.  
 
Fig. 5. Thermal scan at 210nm of purified recombinant CRTAC’s in water, from 20ºC at 90ºC with 1ºC 
temperature measurement step.  
 
In order to analyze the effect of low temperatures and freezing CRTAC’s proteins were 
subjected to 4 cycles of freezing at -80ºC. Far-UV CD spectra after one freezing cycle 
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revealed a loss in secondary structure more pronounced for hCRTAC1 and only in third 
freeze of dlCRTAC2. After the third freezing cycle a shift in the minimum to lower 
wavelength is observed only in hCRTAC1 suggesting an decrease in ordered structure 
(Fig. 6).  
 
 
Fig. 6. Far-UV CD spectra of purified recombinant CRTAC’s proteins in water, after 4 freezing cycles. 
A- dlCRTAC1 meausements of 4 cycles of freezing at -80ºC, B-dlCRTAC2 meausements of 4 cycles of 
freezing at -80ºC, C- hCRTAC1 meausements of 4 cycles of freezing at -80ºC.  
 
3.3.2	  Thermoestability	  of	  CRTAC’s	  
	  
Intrinsic fluorescence emission was used to analyze the tertiary structure and thermal 
stability of recombinant CRTAC’s (1 µM). Proteins contain three amino acid residues, 
tryptophan, tyrosine and phenylalanine, which may contribute to their intrinsic 
fluorescence. CRTAC’s proteins were excited at 280 nm to measure tryptophan 
emission spectrum between 290 and 420 nm using a 1 nm slit width. Proteins were 
solubilized in water in both experimental procedures. All CRTACs show similar 
emission spectra with maximum emission at 338, 339 and 338 for hCRTAC1, 
dlCRTAC1 and dlCRTAC2 respectively. After heating to 90 ºC there was no 
appreciable shift in the emission maximum suggesting that there was no tryptophan 
exposure due to unfolding (Fig 7). These results are in agreement with the CD 
measurements showing that CRTAC´s are thermostable and retain tertiary structure up 
to 90ºC.  These results could be justified by your characteristic of insolubility and 
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ulterior aggregations. Probably both CRTAC’s proteins aggregate before disintegrate 
the secondary and tertiary structure, as was already described 21. One could hypothesize 
that CRTAC´s aggregate forming thermal resistant multimeric structures that retain 3 
dimensional structure.  
 
Fig. 7. Fluorescence emission spectra (λexc=280nm) of native CRTAC’s (1uM) in water at 20 ºC (full 
line) and at 90 ºC (dotted line). 
 
CRTAC’s proteins were submitted to 4 freezing cycles. Spectra obtained do not show 
an appreciable deviation of emission maximum indicative of unfolding. The results 
obtained were consistent with those obtained in the CD measurements suggesting that 
all proteins maintain their native structure. However for hCRTAC1 a shift in emission 
maximum was observed after the first freezing cycle suggesting lower stability (Fig 8). 
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Fig. 8. Fluorescence emission spectra (λexc=280nm) of CRTAC proteins after freezing at -80 ºC. A- 
dlCRTAC1 fluorescence emission measurements of 5 cycles of freezing at -80 ºC, B- dlCRTAC2 
fluorescence emission measurements of 5 cycles of freezing at -80 ºC, C- hCRTAC1 fluorescence 
emission measurements of 5 cycles of freezing at -80 ºC. 
 
3.3.3	  Aggregation	  Assay	  
 
Thioflavin-T assay was used to investigate putative formation of amyloid aggregates by 
CRTACs. When bound to highly beta-sheet rich structures, such as amyloid aggregates, 
ThT emits enhanced florescence 482 nm. CRTAC’s proteins were incubated for 20 days 
at 37ºC and their fluorescence measured in the presence of ThT. Results showed a 
decrease of fluorescence emission relatively to CRTAC’s that were not incubated (Fig. 
9). These results may be due to protein degradation or formation of non-amyloid 
aggregates. The fact that CRTACs are β-sheet rich structures accounts for the hight ThT 
fluorescence in the native state.  
 
Fig. 9. Thioflavin-T assay. Blue bars correspond to the negative control comprising buffer (100 mM Tris-
HCl, 500 mM NaCl, 1 mM CaCl2 at pH 8) without proteins. Red bars correspond to fluorescence 
measurements of dlCRTAC1, dlCRTAC2 and hCRTAC1 respectively, that were not incubated (T=0h). 
Green bars correspond to dlCRTAC1, dlCRTAC2 and hCRTAC1, mixed with Thioflavin-T after 20 days 
of incubation at 37ºC. 
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4. Discussion and conclusions 
 
Human CRTAC1 and piscine dlCRTAC1 and dlCRTAC2 recombinant proteins were 
overexpressed in E.coli  BL21(DE3) and Origami 2 (DE3), in the insoluble cellular 
fraction as inclusion bodies. The introduction of foreign genes for heterologous protein 
production in recombinant expression systems, such as E.coli, often leads to the 
production of expressed proteins as inclusion bodies 28.  
The small-scale optimization results (not shown) suggest that different E.coli strains 
could influence the expression of the recombinant CRTAC´s and E.coli Origami 2 
(DE3) shows to be most efficient for piscine CRTAC´s expression while E.coli 
BL21(DE3) was the most adequated for hCRTAC1 expression. However, the double of 
induction time (12 h) was required for the production of recombinant hCRTAC1 in 
E.coli BL21(DE3) reach a similar level to that of piscine CRTAC's productivity. In 
some cases, cells transfected with recombinant expression vectors modify the intrinsic 
cellular protein levels which adversely affect cell growth 29 and hCRTAC1 required 
more induction time to reach similar expression levels to those of piscine CRTAC´s.  
Contrary to what was observed for human and piscine CRTAC1 form which were 
obtained in a high yield (estimated in 76,52 - 90,91%) after solubilisation, purification 
and refolding process, significant losses (36,46%) of dlCRTAC2 protein occurred and 
the critical steps were the concentration and refolding process. It is known that the 
concentration of some proteins until certain limits induce protein aggregation 30 and the 
refolding process by dialysis promote the proteins to return the right folding, in 
particular proteins rich in disulphide bonds, however under  certain concentration of 
denaturant the proteins may form aggregates that resulting from folding intermediate 
species 31. Similar results were also observed for the recombinant sea bream CRTAC2 
21 that shows a high tendency to form aggregates. CRTAC´s proteins tend to precipitate 
and form aggregates during the recombinant production and this property seems to be 
more pronounced in the teleost CRTAC2 form in comparison with human and teleost 
CRTAC1.  
Solubilisation and refolding process are two essential steps to obtain native protein 
conformation 32. The resulting refolded and solubilized CRTAC´s were used for 
molecular and structural characterization using a comparative approach.  
All CRTAC´s were obtained with high purity and their identity was assessed by mass 
spectrometry that generated a confirmatory peptide mass fingerprint. Beyond the 
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expected MW forms of human and piscine CRTAC´s, an additional smallest protein co-
expressed with dlCRTAC2 was observed and their identity was confirmed as 
dlCRTAC2 that suggest an effect of protein processing by E.coli giving rise to 
alternative CRTAC2 forms. In fact, CRTAC is an ancestral protein present in several 
prokaryotes that possesses domains such as ASPIC/UnbV and several VCBS, which are 
highly conserved and strongly associated with bacteria. 
Purified and refolded CRTAC´s in denaturing conditions shown immunoreactivity with 
specific polyclonal antibodies. Single protein bands with the expected MW were 
observed for each CRTAC in Western blot and this confirm the identity, integrity and 
quality of the resulting recombinant proteins. However, the availability of antibodies 
that allows discriminating between CRTAC1 and 2 is a real challenge due to the high 
degree of similarity (72%) between them. We know in advance that the antiserum 
generated against sea bass CRTAC2 specific peptide is the only specific for CRTAC2 
(results not published) and although the antibodies used to recognize CRTAC1 (human 
or sea bass) cross-react with the two forms (Anjos et al., 2013), the descrimination 
between proteins was also possible due to the MW differences between them (67,9 kDa 
for dlCRTAC1, 68,6 kDa for hCRTAC1 and 56,7k Da for dlCRTAC2).  
Size exclusion chromatography revealed that piscine dlCRTAC1 and dlCRTAC2 form 
mostly aggregates and only very little amounts of monomer are revealed by the small 
peaks. hCRTAC1, however, exhibited appreciable amounts of both the aggregate and 
monomeric form. These findings suggest that piscine CRTACs are less stable or less 
soluble than the human counterpart.  
In previous studies recombinant piscine CRTAC2 revealed its tendency to form 
aggregates under non denaturing conditions, either in vivo and in vitro 21. The aggregate 
propensity of hCRTAC1 has not been previously explored although such tendency is 
suggested by its tissue distribution 19, overexpression in neurodegenerative diseases 15 
and biomarker characteristics 12 suggest .  
Circular Dichroism analysis demonstrated that the native structure of piscine and human 
CRTAC’s is rich in beta-sheet (≈40%), contains approximately 10,3% alpha-helix and 
the remaining is disordered. The high Beta-sheet content of proteins, as CRTAC’s 
coupled together with their high percentage of non-polar hydrophobic amino acid 
residues 19, highlight their tendency to form aggregates. CD analysis showed that 
dlCRTAC1, dlCRTAC2 and hCRTAC1 are highly thermostable as they did not show 
sign of thermal unfolding. However hCRTAC1 showed slightly higher loss of 
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secondary structure comparatively to the piscine forms suggesting that human CRTAC1 
might be less thermostable than piscine CRTAC´s.  
Intrinsic fluorescence emission demonstrated that after heating all CRTAC’s to 90ºC 
there was no appreciable shift in the emission maximum suggesting that there was no 
tryptophane exposure due to unfolding. These results are in agreement with the CD 
measurements showing that CRTAC’s are thermostable and retain tertiary structure up 
to 90ºC, as previously described for sea bream CRTAC2 21. These results could be 
justified by CRTAC´s insolubility and aggregation propensity: One could hypothesize 
that the proteins aggregate before disintegrating their secondary and tertiary structure 21 
and render a highly thermal resistant multimeric structure that retain its 3 dimensional 
structural motifs.  
Fluorescence emission studies after submitting the proteins to several freezing cycles 
also suggest that hCRTAC1 has lower stability than piscine CRTACs: after only one 
freezing cycle hCRTAC1 has a much more pronounced loss of ordered structure 
revealed by a loss of signal in the 215-220 nm range. Curiously after three freezing 
cycles the CD signal becomes larger and more negative with minimum mrw shift to 
lower wavelengths (approximately 208 nm) and more positive at approximately 195 
nm. This may suggest a shift in secondary structure to an increase in alpha-helical 
content. This behaviour is more pronounced for hCRTAC1 and dlCRTAC2 while for 
dlCRTAC1 it is less pronounced and happens only after 4 cycles of freezing. These 
results suggest that dlCRTAC1 is more stable and perhaps dlCRTAC2 is more flexible 
and prone to conformational changes. hCRTAC1 seems to be less stable in general.  
Thioflavin T is a dye which bind β-sheet structure and its used for identification of 
amyloid fiber formation due to the highly packed β-sheet structure of amyloids 33. We 
used this dye to test if CRTACs form amyloid-like structures after incubation at 37ºC.  
Thioflavin-T assays showed a decrease in fluorescence emission for CRTACs incubated 
at 37ºC comparatively to non-incubated CRTAC. The fact that ThioflavinT 
fluorescence decreased after incubation may suggest protein degradation or structure 
loss due to the long period of incubation or formations of non-amyloid aggregates. 
Nevertheless the formation of amyloid structures by CRTAC´s should not be discarded. 
The fact that the protein forms very easily large aggregates that seem to retain tertiary 
structure suggests that CRTAC aggregates could have a functional role. Weather 
CRTAC aggregation can lead to amyloid formation remains to be established. The fact 
that fresh CRTACs exhibit high ThioflavinT fluorescence could be explained by their 
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high intrinsic β-sheet content or perhaps a “native” functional amyloid-like 
conformation that can provide binding sites for Thioflavin-T. Such idea is supported by 
the evidence that CRTAC´s form large aggregates in vivo 21. Functional amyloids have 
previously been reported. For example E.coli amyloid curli, form extracellular fibers 
highly stable, insoluble and high molecular weight protein complexes rich in beta sheet 
secondary structure 34. The existence of functional amyloids could explanation the 
tendency of certain proteins to aggregate 35. 
In conclusion, structural studies demonstrated that CRTAC’s were thermostable to 
heating and freezing effect and probably has the ability to retain your secondary and 
tertiary structure. The beta-sheet conformation and hydrophobic composition indicate 
the proteins most probably aggregate. The presence of functional amyloid and 
crystallography knowledge coud explain a tendency of certain proteins aggregate. 
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Chapter IV 
Future perspectives 
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Future perspectives 
 
 
In the present study the recombinant hCRTAC1 and piscine CRTAC1 and 2 proteins 
were generated in large-scale production and this are valuable tools that will permit in 
the future the development of structural and functional studies to establish the actions of 
this enigmatic protein.  
The fact that CRTAC´s tends to form very easily large aggregates that retain their 
tertiary structure and that are highly thermostable suggest that such aggregates could 
have a functional role. This idea is supported by the evidence that CRTAC´s form large 
aggregates in vivo21. Clarify the type and mechanisms and dynamics of aggregates 
formed by CRTAC´s will be important in the future in order to establish if they are 
functional structures (non-pathological proteins) or are involved in pathologies and this 
will be of considerable interest for medicine and pharmaceutical industries. Your 
tendency to aggregate should be assessed in future studies in vivo and in vitro and  the 
results may be the answer in diseases where this proteins are involved. Moreover, the 
CRTAC´s ubiquitous tissue distribution 21 19 and association with a number of 
pathologies (US20120231477 A1) suggest an important role for this protein in health 
and disease.  
The resolution of CRTAC´s crystal structures (3D structures) will be also of relevant 
interest, as future perspective, to give insights about protein function, evolution and the 
resulting information could contribute to explain the tendency of certain proteins to 
aggregate. 
Comparative analysis between human and piscine CRTAC´s may contribute to 
understand protein folding, stability and give insights about the functional evolution and 
this information will certainly be of importance for medical application and 
pharmaceutical and biotechnological industries. 
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Appendix 1 
 
 
 
 
 
 
Protein ID MASCOT 
cartilage acidic protein 1 isoform X1 [Homo sapiens] gi|530393911  
Mr(Da)= 68600 
pI= 5,05 
   1 MAPSADPGMS RMLPFLLLLW FLPITEGSQR AEPMFTAVTN SVLPPDYDSN  
   51 PTQLNYGVAV TDVDHDGDFE IVVAGYNGPN LVLKYDRAQK RLVNIAVDER  
   101 SSPYYALRDR QGNAIGVTAC DIDGDGREEI YFLNTNNAFS GVATYTDKLF  
   151 KFRNNRWEDI LSDEVNVARG VASLFAGRSV ACVDRKGSGR YSIYIANYAY  
   201 GNVGPDALIE MDPEASDLSR GILALRDVAA EAGVSKYTGG RGVSVGPILS  
   251 SSASDIFCDN ENGPNFLFHN RGDGTFVDAA ASAGVDDPHQ HGRGVALADF  
   301 NRDGKVDIVY GNWNGPHRLY LQMSTHGKVR FRDIASPKFS MPSPVRTVIT  
   351 ADFDNDQELE IFFNNIAYRS SSANRLFRVI RREHGDPLIE ELNPGDALEP  
   401 EGRGTGGVVT DFDGDGMLDL ILSHGESMAQ PLSVFRGNQG FNNNWLRVVP  
   451 RTRFGAFARG AKVVLYTKKS GAHLRIIDGG SGYLCEMEPV AHFGLGKDEA  
   501 SSVEVTWPDG KMVSRNVASG EMNSVLEILY PRDEDTLQDP APLECGQGFS  
   551 QQENGHCMDT NECIQFPFVC PRDKPVCVNT YGSYRCRTNK KCSRGYEPNE  
   601 DGTACVERTL LLGLCNLLGK  
Protein ID MASCOT 
Cartilage acidic protein 1 [Tetraodon nigroviridis] gi|85838736  
Mr(Da)= 69600 
pI= 5,42 
    1 MLAWVLLFLP PVSSAQRSEP VFSSITKSIL PPNYENNPTQ LNYGVAVTDV  
    51 DGDGDLEVFV AGYNGPNLVL KYIQDQKRLV NIAVDNRSSP FYALRDRQGN  
   101 AIGVTACDID GDGREEIYVL NTNNAFSGRA TYSDKLFKFR NGRFEDLLND  
   151 DINEHRDVAN RMAGRSVACV DRKGTGRYAI YIANYASGNV GPHALIEMDE  
   201 LASDLSQGVI ALSNVAEEAG VNKFTGGRGV VVGPILNQIL PDVFCDNEYG  
   251 PNFLFRNNGD GTFTDVAQQA GVEDPMQHGR GVALADFNRD GRTDIVYGNW  
   301 NGPHRLFMQL NNRRQKFKDI ASQKFSMPSP VRTVIAADFD NDNELEVFFN  
   351 NIAYRGPSAN RLFRVSRREH GDPQIEELNV GEASEPEGRG TGAVATDFDG  
   401 DGRLELLVSH GESAAQPLSV YKVLQGTSNS WLRVIPRTKF GAFARGAKVV  
   451 VYTKKSGTHT RIIDGGSGYL CEMEPVAHFG LGKDVATGVE VYWPDGRSVV  
   501 RLLEPSDLNS VLEIQYPRDV EVTPTAQTEC GHGFALNEKG RCTDEDECTR  
   551 YPFACPLDRP VCVNTYGSYR CRAKRRCNQG FEPSDDGSAC VGQVAYFGGT  
   601 RSFADRKWSG LCFWLLLPHV LRPGLL 
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I- Identification of CRTACs proteins by searching with tryptic peptide sequence against primary 
sequence databases, using the MASCOT search. dlCRTAC2 protein and dlCRTAC2(small band) 
identification was occur by searching with tryptic peptide sequence against own sequence.  
The dlCRTAC2(small band) was visualized in Fig, 1B (Pag 31) (Orange square).
Protein ID MASCOT 
dlCRTAC2 against own sequence   
Mr(Da)= 59200 
pI= 5,03 
      1 MWASGLLLFL VGLWHQSRAQ GSEPMLRVVT ETMLPPDSLH NPTQLNYGMA  
    51 VTDVDGDGDL EVVVAGYNGP NLVLKYDRTQ NRLVNIAIDD SNSPYYALRD  
   101 RAGNAIGVTA CDVDGDGREE IYFLNTNNAY SGRATYSDKL FKFRNGRFED  
   151 LLSDELNVRR GVANRMAGRS VACIDRKGTG RYSVYVANYA SGNVGPHALL  
   201 EMDETASDVA KGIIALSDVA AVAGVNKFTG GRGVVVGPIL SQSRSDVFCD  
   251 NENGPNFLFK NNGDGTFVDM ARQAGVEDRY QHGRGVALAD FNGDGKTDII  
   301 YGNWNGPHRL FLQGSDSTFR NIATGGFAAP SPIRTVIAAD LDNDKELDVF  
   351 FNNIAYRGNA PNRLFRVSRR ANADPLIQEL NVGDAAEPEG RGTGGTVTDF  
   401 DGDGQLDLLL AHGESARQPI SVFKVTQGSS NNWLRVIPRT QFGSFARGAK  
   451 VTAFTSQSGA HTRIIDGGSG YLCEMEPVAH FGLGNDEVTV LEVSWPDGSS  
   501 ITRTLQSGEM NSVVEVAYPK EGETFLLAND TQCGNGFTVK NGHCAGL 
Protein ID MASCOT 
dlCRTAC2 against own sequence  (small band) 
Mr(Da)= 37000 
    1 MWASGLLLFL VGLWHQSRAQ GSEPMLRVVT ETMLPPDSLH NPTQLNYGMA  
    51 VTDVDGDGDL EVVVAGYNGP NLVLKYDRTQ NRLVNIAIDD SNSPYYALRD  
   101 RAGNAIGVTA CDVDGDGREE IYFLNTNNAY SGRATYSDKL FKFRNGRFED  
   151 LLSDELNVRR GVANRMAGRS VACIDRKGTG RYSVYVANYA SGNVGPHALL  
   201 EMDETASDVA KGIIALSDVA AVAGVNKFTG GRGVVVGPIL SQSRSDVFCD  
   251 NENGPNFLFK NNGDGTFVDM ARQAGVEDRY QHGRGVALAD FNGDGKTDII  
   301 YGNWNGPHRL FLQGSDSTFR NIATGGFAAP SPIRTVIAAD LDNDKELDVF  
   351 FNNIAYRGNA PNRLFRVSRR ANADPLIQEL NVGDAAEPEG RGTGGTVTDF  
   401 DGDGQLDLLL AHGESARQPI SVFKVTQGSS NNWLRVIPRT QFGSFARGAK  
   451 VTAFTSQSGA HTRIIDGGSG YLCEMEPVAH FGLGNDEVTV LEVSWPDGSS  
   501 ITRTLQSGEM NSVVEVAYPK EGETFLLAND TQCGNGFTVK NGHCAGL 
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